Why MiniMed Stock Was Soaring This Week
It easily topped analyst revenue estimates in its opening quarter of fiscal 2027.
Overview
Highly specialized medical device maker MiniMed Group (NASDAQ: MMED) was highly prized by investors over the past few trading days. That stood to reason, as the company unveiled first-quarter fiscal 2027 results that comfortably exceeded revenue expectations.
As of late Thursday evening, the company's shares were up by nearly 19% week to date, according to data compiled by S&P Global Market Intelligence.
Details
MiniMed, which focuses on diabetes care, booked net sales of $843 million, up a sturdy 17% year over year. Much of this came from outside our borders, as international net sales rose by 18% to hit $603 million. That figure for the medical device company's native U.S. market was $240 million, 13% higher than the same quarter of fiscal 2026.
Source
Originally published at www.fool.com.